Sherry has over 20 years of experience in strategic consulting, marketing strategy, business innovation, product and franchise optimization, sales operations, market research and regulatory affairs. Her client engagements include mobile health and telemedicine solutions, innovation in personalized medicine and diagnostics, health IT and hospital solutions, and product portfolio strategies. She has cultivated experience in a broad array of therapeutic areas including neurology, psychiatry, gastroenterology, endocrinology, oncology, anti-infectives, respiratory, women’s health, cognitive health, and nephrology.
This diverse skill set dovetails well with the recent culture of open innovation in healthcare, with engagements focusing on growth strategies for products, portfolios, and adjacencies; innovation in personalized medicine, diagnostics, health information technology, and hospital solutions; and commercial landscape and opportunity assessments in emerging ecosystems.
Previously, Sherry was a Director of Marketing at Amgen, with responsibility for a U.S. and global nephrology product launch, a Vice President at Migliara/Kaplan Associates (now Kantar Health), and a Regulatory Review Officer at the FDA with responsibility for drug labeling and other branding materials for neuropharmacology, oncology, respiratory, and anti-infectives drug products. She began her career as a sales & marketing representative for Eli Lilly and Company.
Sherry earned a B.S. in Chemistry from the University of Virginia and an M.B.A. from the University of Virginia’s Darden School of Business.